Sclerostin
Open accessAbstract
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sclerostin inhibits bone formation.
“Sclerostin inhibits bone formation163,164 and blood levels of sclerostin are lower in highly active humans than in sedentary humans163.”
From Exerkines in health, resilience and disease (2022) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Towards an integrated view of Wnt signaling in development
van Amerongen, R., & Nusse, R. (2009) · Development · doi:10.1242/dev.033910 · Cited by 1,168 · see citing works
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147 · see citing works
Li, X., Ominsky, M. S., Niu, Q., Sun, N., Daugherty, B., D’Agostin, D. M., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 938 · see citing works
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784 · see citing works
Lin, C., Jiang, X., Dai, Z., Guo, X., Weng, T., Wang, J., Li, Y., Feng, G., Gao, X., & He, L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090411 · Cited by 631 · see citing works
Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G. J., Gong, J., Gao, Y., Cao, J., Graham, K. C., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414 · see citing works
Mirza, F., Padhi, I. D., Raisz, L. G., & Lorenzo, J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2283 · Cited by 312 · see citing works
Wnt signaling as a therapeutic target for bone diseases
Hoeppner, L. H., Secreto, F. J., & Westendorf, J. J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902841961 · Cited by 238 · see citing works
Eddleston, A., Marenzana, M., Moore, A., Stephens, P. E., Muzylak, M., Marshall, D., & Robinson, M. K. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090403 · Cited by 98 · see citing works
Case 150: Van Buchem Disease (Hyperostosis Corticalis Generalisata)
Wengenroth, M., Vasvari, G. P., Federspil, P. A., et al. (2009) · Radiology · doi:10.1148/radiol.2531080011 · Cited by 27 · see citing works
Lane, N. E., & Silverman, S. L. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0005-4 · Cited by 27 · see citing works
Self-citationThe promise of sclerostin inhibition for the treatment of osteoporosis
Kneissel, M. (2009) · IBMS BoneKEy · doi:10.1138/20090388 · Cited by 19 · see citing works
Shane, E. J. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.07vd01 · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 7
- [7]Jilka R Climer L De Loose A Balanced remodeling in response to sustained PTH elevation requires osteoclastic bone resorption, sclerostin suppresion, as well as increased angiogenesis In: Proceedings of the ASBMR Annual Meeting 2009
- [11]Ke HZ Xiang JJ Li X Inhibition of sclerostin by systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in mice and rats In: Proceedings of the 55th Annual Orthopedic Research Society Meeting February 2009 Las Vegas, Nev, USA
- [12]Li X Warmington K Niu Q Increased bone formation and bone mass by sclerostin antibody was not blunted by pretreatment with alendronate in ovariectomized rats with established osteopenia In: Proceedings of the ASBMR Annual Meeting 2009
- [13]Halleux C Hu S Diefenbach B Infrequent cotreatment and sequential treatment of antisclerostin antibody with zoledronic acid restores and maintains bone mass in murine osteoporosis models In: Proceedings of the ASBMR Annual Meeting 2009
- [14]Lane N Dai W Yao W Treatment with sclerostin inhibitors increases bone formation in male mice In: Proceedings of the ASBMR Annual Meeting 2009
- [16]Ominsky M Samadfam R Jolette J Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in af primate fibular osteotomy model In: Proceedings of the ASBMR Annual Meeting 2009
- [17]Padhi D Stouch B Jang G Antisclerostin antibody increases markers of bone formation in healthy postmenopausal women Journal of Bone and Mineral Research 2007 22 S1 S371
Cited by
Sorted by citations
Exerkines in health, resilience and disease
Chow, L. S., Gerszten, R. E., Taylor, J. M., Pedersen, B. K., van Praag, H., Trappe, S., Febbraio, M. A., Galis, Z. S., Gao, Y., Haus, J. M., et al. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00641-2 · Cited by 927 · see citing works
- Authors
- Silverman, S. L.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Silverman, Stuart L.
- ORCID
- Silverman, Stuart L.
- Venue
- Journal of Osteoporosis
- Publisher
- Hindawi Limited
- Published
- 2010
- Volume
- 2010
- Pages
- 1-3
- ISSN
- 2042-0064 (ISSN-L)
- PMC
- PMC2957275
- OpenAlex
- W4236849067
- Cited by
- 30
- References
- 13
- Citations by year
- 2023: 1 · 2022: 5 · 2021: 3 · 2019: 1 · 2018: 6 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 6 · 2012: 1
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Osteoporosis (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Keywords
- sclerostin, monoclonal antibodies, osteoporosis, parathyroid hormone, bone formation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
